高级检索
当前位置: 首页 > 详情页

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ ESCI

机构: [1]Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China [2]Hebei Univ,Affiliated Hosp,Dept Med Oncol,Baoding,Peoples R China [3]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Resp Dis, Hangzhou, Peoples R China [4]Shanghai Jiao Tong Univ, Renji Hosp, Dept Resp & Crit Care Med, Sch Med, Shanghai, Peoples R China [5]Dalian Med Univ, Hosp 2, Dept Thorac Med Oncol 2, Dalian, Peoples R China [6]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Resp & Crit Care Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China [7]Shanghai Jiao Tong Univ, Clin Res Inst, Sch Med, Dept Biostat, Shanghai, Peoples R China [8]Baotou Tumor Hosp, Internal Med Thorac Oncol, Baotou, Peoples R China [9]Shaanxi Med Univ, Affiliated Bethune Hosp, Dept Thorac Oncol, Taiyuan, Peoples R China [10]Soochow Univ, Affiliated Hosp 1, Dept Med Resp Emergency & Intens Care Med, Suzhou, Peoples R China [11]Inner Mongolia Autonomous Reg Peoples Hosp, Canc Ctr, Hohhot, Peoples R China [12]Xinjiang Med Univ, Affiliated Tumor Hosp, Ward 2, Dept Pulm Med, Urumqi, Peoples R China [13]Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China [14]Cixi Peoples Hosp, Dept Thorac Surg, Ningbo, Peoples R China [15]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China [16]Zhejiang A&F Univ, Coll Math & Comp Sci, Hangzhou, Peoples R China [17]Metafame Technol Inc, Shanghai, Peoples R China
出处:
DOI: 10.2196/45331
ISSN:

关键词: telehealth real-world data patient engagement lung carcinoma patient-reported outcomes

摘要:
Background: Telehealth has emerged as a popular channel for providing outpatient services in many countries. However, the majority of telehealth systems focus on operational functions and offer only a sectional patient journey at most. Experiences with incorporating longitudinal real -world medical record data into telehealth are valuable but have not been widely shared. The feasibility and usability of such a telehealth platform, with comprehensive, real -world data via a live feed, for cancer patient care are yet to be studied. Objective: The primary purpose of this study is to understand the feasibility and usability of cancer patient care using a telehealth platform with longitudinal, real -world data via a live feed as a supplement to hospital electronic medical record systems specifically from physician's perspective. Methods: A telehealth platform was constructed and launched for both physicians and patients. Real -world data were collected and curated using a comprehensive data model. Physician activities on the platform were recorded as system logs and analyzed. In February 2023, a survey was conducted among the platform's registered physicians to assess the specific areas of patient care and to quantify their before and after experiences, including the number of patients managed, time spent, dropout rate, visit rate, and follow-up data. Descriptive and inferential statistical analyses were performed on the data sets. Results: Over a period of 15 months, 16,035 unique users (13,888 patients, 1539 friends and family members, and 174 physician groups with 608 individuals) registered on the platform. More than 382,000 messages including text, reminders, and pictures were generated by physicians when communicating with patients. The survey was completed by 78 group leaders (45% of the 174 physician groups). Of the participants, 84% (65.6/78; SD 8.7) reported a positive experience, with efficient communication, remote supervision, quicker response to questions, adverse event prevention, more complete follow-up data, patient risk reduction, cross -organization collaboration, and a reduction in in -person visits. The majority of the participants (59/78, 76% to 76/78, 97.4%) estimated improvements in time spent, number of patients managed, the drop-off rate, and access to medical history, with the average ranging from 57% to 105%. When compared with prior platforms, responses from physicians indicated better experiences in terms of time spent, the drop-off rate, and medical history, while the number of patients managed did not significantly change. Conclusions: This study suggests that a telehealth platform, equipped with comprehensive, real -world data via a live feed, is feasible and effective for cancer patient care. It enhances inpatient management by improving time efficiencies, reducing drop-off rates, and providing easy access to medical history. Moreover, it fosters a positive experience in physician -patient interactions.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [6]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Resp & Crit Care Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China [*1]Department of Respiratory and Critical Care Medicine Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine No 241 West Huaihai Rd Shanghai, 200030 China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis [2]Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study [3]Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus ge fi tinib as fi rst-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer [4]The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China [5]Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma(Open Access) [6]The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis [7]Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin [8]Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma [9]parp抑制剂与替莫唑胺在mgmt高表达的肺癌脑转移中有协同作用 [10]Application of Molecular Detection of Lung Cancer in Developing Countries

资源点击量:15101 今日访问量:4 总访问量:964 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号